Aligos Therapeutics Inc
ALGS
Company Profile
Business description
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Contact
One Corporate Drive
2nd Floor
South San FranciscoCA94080
USAT: +1 800 466-6059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
70
Stocks News & Analysis
stocks
Earnings winners: BHP, NAB & TLS lead the pack
The winners of this weeks earnings that saw strong investor backing
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
We think Walmart stock is significantly overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.20 | 9.30 | 0.10% |
| CAC 40 | 8,515.49 | 116.71 | 1.39% |
| DAX 40 | 25,260.69 | 217.12 | 0.87% |
| Dow JONES (US) | 49,588.98 | 193.82 | 0.39% |
| FTSE 100 | 10,686.89 | 59.85 | 0.56% |
| HKSE | 26,413.35 | 292.59 | -1.10% |
| NASDAQ | 22,875.73 | 193.00 | 0.85% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,308.52 | 135.68 | -1.01% |
| S&P 500 | 6,905.36 | 43.47 | 0.63% |
| S&P/ASX 200 | 9,081.40 | 17.00 | 0.19% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |